Physician profile
Nathan G Momberger
NPI 1467486795
$3,018,290.97
in general payments reported to CMS, 2019-2025
12 companies · $568K in 2025
The $568K reported for 2025 was more than what 97% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362K · 2020: $325K · 2021: $368K · 2022: $390K · 2023: $473K · 2024: $531K · 2025: $568K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.6M · Consulting Fee: $1,400 · Travel and Lodging: $1,096 · Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,569,202.96 |
| Consulting Fee | $1,400.00 |
| Travel and Lodging | $1,096.08 |
| Food and Beverage | $783.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Development Corporation | $3,011,479.28 | 2019-2025 | |
| Medical Device Business Services, INC. | $2,353.57 | 2019-2025 | Attune |
| Depuy Synthes Sales INC. | $2,140.10 | 2019-2025 | Velys |
| Stryker Corporation | $1,808.65 | 2021-2022 | |
| Think Surgical, INC. | $207.19 | 2024 | |
| Zimmer Biomet Holdings, INC. | $148.36 | 2021 | |
| Pfizer INC. | $76.79 | 2021-2023 | |
| Avanos Medical | $17.58 | 2021 | |
| Bioventus LLC | $16.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.39 | 2022 | |
| Medacta USA, INC. | $14.45 | 2019 | |
| Davol INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Momberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.